Longitudinal measurements of renal and systemic concentrations of IGF2 and IGFBP2 in diabetes and diabetic nephropathy will be needed to clarify which of these potential mechanisms results in the independent relation between higher circulating IGFBP2 and more adverse renal outcome over time. The gene discussed is IGFBP2; the disease is diabetic kidney disease.